Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-861 in Narcolepsy Type 1
NCT06470828Phase 3Completed
- Sponsor
- Takeda
- Start
- Jul 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of oveporexton in narcolepsy type 1 (NT1), sponsored by Takeda. Started Jul 2024; status: completed.
02
Drugs
oveporexton
03
Conditions
narcolepsy type 1 (NT1)
Beyond the preview
Go deeper on NCT06470828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06470828.